Mantle cell lymphoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 20
• BTK 17
• CD20 8
• TP53 2
• BCL-2 5
• PI3K 0
• CD22 3
• MYC 0
• PD-1 2
• CXCR4 0
• EGFR 0
• PD-L1 1
• PRMT5 0
• ALK 0
• CD47 0
• JAK 0
• STAT3 0
• AKT 0
• ATM 0
• BRCA1 1
• BRCA2 1
• BRD4 0
• CCR5 0
• CD40 0
• FLT3 0
• GPX4 0
• HDAC 0
• HSP90 0
• KMT2A 0
• MET 0
• mTOR 0

24 of 39+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Phase 1 Study of ADI-001 in B Cell Malignancies

  NCT04735471· Adicet Therapeutics· Updated 18 Jun 2025

  “Terminated - Halted Prematurely”Registry text, quoted unchanged. Source

• Terminated

  Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

  NCT05360238· Mustang Bio· Updated 22 Jul 2024

  “Business reasons”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  NCT06542250· AstraZeneca· Source

• A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

  NCT03888105· Regeneron Pharmaceuticals· Source

• Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

  NCT04599634· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• Gene Expression Profiling 6
• Proteomics 1
• Flow Cytometry 6
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 7
• Magnetic Resonance Imaging 1
• Machine Learning 2
• Deep Learning 1
• Cohort Studies 2

• Proteogenomic features define subtypes of mantle cell lymphoma.

  Blood Adv, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.